Tags

Type your tag names separated by a space and hit enter

Effect of edaravone on the estimated glomerular filtration rate in patients with acute ischemic stroke and chronic kidney disease.
J Stroke Cerebrovasc Dis. 2011 Mar-Apr; 20(2):111-6.JS

Abstract

The oxygen free radical scavenger edaravone is used in patients with acute ischemic stroke in Japan, but adverse reactions, especially decreased renal function, have raised concerns. To examine whether a patient's estimated glomerular filtration rate (eGFR) at admission can predict renal function deterioration after edaravone treatment, we retrospectively evaluated the effect of edaravone on eGFR in Japanese patients with acute ischemic stroke and chronic kidney disease (CKD). The baseline eGFR in the edaravone-treated group (73.5±20.3 mL/min/1.73 m(2); n=408) at admission was significantly (P < .05) higher than that in the non-edaravone-treated group (51.9±25.2 mL/min/1.73 m(2); n=41). The change in eGFR after treatment was categorized into 3 grades: nonexacerbation (≤10%), 10%-30% exacerbation, and >30% exacerbation. There was no significant difference in exacerbation grade between the edaravone-treated and non-edaravone-treated groups (χ(2) =3.134; P=.21). We next subdivided the edaravone-treated group according to eGFR at admission as either CKD (eGFR <60 mL/min/1.73 m(2); n=111) and non-CKD (n=297). No significant decrease in eGFR was seen even in the edaravone-treated CKD group (most of whom were in stage 3 CKD). Decreased eGFR in stroke patients was found to be associated with stroke subtype (cardiogenic stroke), but not with infection. The present study demonstrates that eGFR at admission is not a good predictor of renal deterioration in edavarone-treated acute ischemic stroke patients, including those with stage 3 CKD.

Authors+Show Affiliations

Division of Neurology, Department of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

20580255

Citation

Tsukamoto, Yuuko, et al. "Effect of Edaravone On the Estimated Glomerular Filtration Rate in Patients With Acute Ischemic Stroke and Chronic Kidney Disease." Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association, vol. 20, no. 2, 2011, pp. 111-6.
Tsukamoto Y, Takizawa S, Takahashi W, et al. Effect of edaravone on the estimated glomerular filtration rate in patients with acute ischemic stroke and chronic kidney disease. J Stroke Cerebrovasc Dis. 2011;20(2):111-6.
Tsukamoto, Y., Takizawa, S., Takahashi, W., Mase, H., Miyachi, H., Miyata, T., & Takagi, S. (2011). Effect of edaravone on the estimated glomerular filtration rate in patients with acute ischemic stroke and chronic kidney disease. Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association, 20(2), 111-6. https://doi.org/10.1016/j.jstrokecerebrovasdis.2009.11.008
Tsukamoto Y, et al. Effect of Edaravone On the Estimated Glomerular Filtration Rate in Patients With Acute Ischemic Stroke and Chronic Kidney Disease. J Stroke Cerebrovasc Dis. 2011 Mar-Apr;20(2):111-6. PubMed PMID: 20580255.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of edaravone on the estimated glomerular filtration rate in patients with acute ischemic stroke and chronic kidney disease. AU - Tsukamoto,Yuuko, AU - Takizawa,Shunya, AU - Takahashi,Wakoh, AU - Mase,Hiroyasu, AU - Miyachi,Hayato, AU - Miyata,Toshio, AU - Takagi,Shigeharu, Y1 - 2010/06/26/ PY - 2009/09/05/received PY - 2009/10/25/revised PY - 2009/11/05/accepted PY - 2010/6/29/entrez PY - 2010/6/29/pubmed PY - 2011/6/18/medline SP - 111 EP - 6 JF - Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association JO - J Stroke Cerebrovasc Dis VL - 20 IS - 2 N2 - The oxygen free radical scavenger edaravone is used in patients with acute ischemic stroke in Japan, but adverse reactions, especially decreased renal function, have raised concerns. To examine whether a patient's estimated glomerular filtration rate (eGFR) at admission can predict renal function deterioration after edaravone treatment, we retrospectively evaluated the effect of edaravone on eGFR in Japanese patients with acute ischemic stroke and chronic kidney disease (CKD). The baseline eGFR in the edaravone-treated group (73.5±20.3 mL/min/1.73 m(2); n=408) at admission was significantly (P < .05) higher than that in the non-edaravone-treated group (51.9±25.2 mL/min/1.73 m(2); n=41). The change in eGFR after treatment was categorized into 3 grades: nonexacerbation (≤10%), 10%-30% exacerbation, and >30% exacerbation. There was no significant difference in exacerbation grade between the edaravone-treated and non-edaravone-treated groups (χ(2) =3.134; P=.21). We next subdivided the edaravone-treated group according to eGFR at admission as either CKD (eGFR <60 mL/min/1.73 m(2); n=111) and non-CKD (n=297). No significant decrease in eGFR was seen even in the edaravone-treated CKD group (most of whom were in stage 3 CKD). Decreased eGFR in stroke patients was found to be associated with stroke subtype (cardiogenic stroke), but not with infection. The present study demonstrates that eGFR at admission is not a good predictor of renal deterioration in edavarone-treated acute ischemic stroke patients, including those with stage 3 CKD. SN - 1532-8511 UR - https://www.unboundmedicine.com/medline/citation/20580255/Effect_of_edaravone_on_the_estimated_glomerular_filtration_rate_in_patients_with_acute_ischemic_stroke_and_chronic_kidney_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1052-3057(09)00252-3 DB - PRIME DP - Unbound Medicine ER -